Continuously active disinfectant inactivates severe acute respiratory coronavirus virus 2 (SARS-CoV-2) and human coronavirus 229E two days after the disinfectant was applied and following wear exposures
Name:
continuously-active-disinfecta ...
Size:
133.4Kb
Format:
PDF
Description:
Final Published Version
Affiliation
Department of Environmental Science, University of ArizonaIssue Date
2021-12-08
Metadata
Show full item recordPublisher
Cambridge University PressCitation
Rutala WA, Ikner LA, Donskey CJ, Weber DJ, Gerba CP. Continuously active disinfectant inactivates severe acute respiratory coronavirus virus 2 (SARS-CoV-2) and human coronavirus 229E two days after the disinfectant was applied and following wear exposures. Infection Control & Hospital Epidemiology. 2023;44(3):507-509. doi:10.1017/ice.2021.481Rights
© The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/).Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
The surface environment in rooms of coronavirus disease 2019 (COVID-19) patients may be persistently contaminated despite disinfection. A continuously active disinfectant demonstrated excellent sustained antiviral activity following a 48-hour period of wear and abrasion exposures with reinoculations. Reductions of >4-log10 were achieved within a 1-minute contact time for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) and the human coronavirus, 229E. © The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America.Note
Open access articleISSN
0899-823XPubMed ID
34852869Version
Final Published Versionae974a485f413a2113503eed53cd6c53
10.1017/ice.2021.481
Scopus Count
Collections
Except where otherwise noted, this item's license is described as © The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/).
Related articles
- Assessment of Antiviral Coatings for High-Touch Surfaces by Using Human Coronaviruses HCoV-229E and SARS-CoV-2.
- Authors: Butot S, Baert L, Zuber S
- Issue date: 2021 Sep 10
- Inactivation of SARS-CoV-2 and HCoV-229E in vitro by ColdZyme® a medical device mouth spray against the common cold.
- Authors: Gudmundsdottir Á, Scheving R, Lindberg F, Stefansson B
- Issue date: 2021 Mar
- Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication.
- Authors: Yamaya M, Nishimura H, Deng X, Kikuchi A, Nagatomi R
- Issue date: 2020 May
- Airborne Disinfection by Dry Fogging Efficiently Inactivates Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Mycobacteria, and Bacterial Spores and Shows Limitations of Commercial Spore Carriers.
- Authors: Schinköthe J, Scheinemann HA, Diederich S, Freese H, Eschbaumer M, Teifke JP, Reiche S
- Issue date: 2021 Jan 15
- Viral Inactivation with Emphasis on SARS-CoV-2 Using Physical and Chemical Disinfectants.
- Authors: Fadaei A
- Issue date: 2021